Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Chronic inflammatory demyelinating polyneuropathy

Launch
Not announced
Last updated
143 sources

Clinical evidence

DNTH103-AU-001

46 evidence topics · 9 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results
Part C pharmacokinetics after immunoglobulin G

No evidence found.

Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Part C safety

No evidence found.

Study limitations
Summary

DNTH103-AU-001 enrolled healthy adults aged 18 to 65 years and excluded people with a history of autoimmune disease, so its safety, pharmacokinetic, and pharmacodynamic findings come from a population without the diseases claseprubart is being developed to treat, and the company states that the same results may not be seen in patients in later trials. Each dose cohort was planned with 8 participants (6 receiving DNTH103 and 2 receiving placebo); the company's top-line announcement reported 52 healthy volunteers in 7 single and multiple ascending dose cohorts, and later company documents reported 60 healthy volunteers in 8 cohorts who completed dosing as of December 2023, while the registry records a final accrual of 68 for Parts A and B and 9 for the open-label, uncontrolled Part C. The Parts A and B registry record lists recruitment in Christchurch, New Zealand, the company states that the phase 1 trial was conducted in New Zealand, and both registry records state that no documents have been uploaded by study researchers, so the available results come from company press releases, presentations, and annual reports, and no Part C result has been reported. The company states that FDA acceptance of data from trials conducted outside the United States is subject to conditions the FDA imposes.